Welcome to Zyngenia Inc.—a biotherapeutics company that is focused on developing a new class of biotherapeutics to address the complexity of diseases by simultaneously targeting multiple biological pathways. Learn More.
Here at Zyngenia Inc., our experts:
Develop smartly engineered monoclonal antibody-based therapeutics, thereby creating opportunities for new biologic activities by the simultaneous targeting of multiple pathways.
Address unmet needs in the treatment of cancer, inflammation, and autoimmune disorders
Develop enhanced and more comprehensive disease intervention with the cost and development paradigm of a single biologic agent.
